CLCN5

From WikiMD's WELLNESSPEDIA

CLCN5 is a gene that encodes the protein chloride channel 5, which is a member of the CLC family of chloride channels and transporters. This protein is primarily expressed in the kidney and plays a crucial role in the reabsorption of chloride ions in the proximal tubules.

Function[edit]

The CLCN5 protein is involved in the regulation of chloride ion transport across cell membranes. It functions as an electrogenic antiporter, exchanging chloride ions for protons. This activity is essential for maintaining the proper ionic balance and pH within the kidney cells, which is critical for the reabsorption of various solutes and water.

Clinical Significance[edit]

Mutations in the CLCN5 gene are associated with Dent's disease, a rare X-linked recessive disorder characterized by low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, and progressive renal failure. Patients with Dent's disease often present with symptoms such as kidney stones, bone demineralization, and renal tubular acidosis.

Pathophysiology[edit]

The mutations in CLCN5 disrupt the normal function of the chloride channel, leading to impaired reabsorption of filtered proteins and other solutes in the proximal tubules. This results in the characteristic features of Dent's disease, including proteinuria and hypercalciuria. The accumulation of calcium in the kidneys can lead to nephrocalcinosis and eventually to chronic kidney disease.

Diagnosis[edit]

The diagnosis of Dent's disease is typically based on clinical features, family history, and genetic testing to identify mutations in the CLCN5 gene. Urinalysis may reveal low molecular weight proteinuria, and imaging studies can detect nephrocalcinosis.

Treatment[edit]

There is currently no cure for Dent's disease, and treatment is primarily supportive. Management strategies include maintaining adequate hydration, using thiazide diuretics to reduce hypercalciuria, and monitoring and treating complications such as kidney stones and bone demineralization.

See Also[edit]

References[edit]

External Links[edit]

-

This article is a stub related to hospitals. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.